Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore

INTRODUCTION: Ustekinumab is a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, and it is approved for the treatment of moderate to severe plaque psoriasis. In this study, we assessed the efficacy and safety of patients receiving ustekinumab for psoriasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wai Sze Agnes, Wong, Yisheng, Oon, Hazel Hwee Boon, Theng, Colin Thiam Seng, Chong, Wei-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395811/
https://www.ncbi.nlm.nih.gov/pubmed/35196847
http://dx.doi.org/10.11622/smedj.2022029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395811/
https://www.ncbi.nlm.nih.gov/pubmed/35196847
http://dx.doi.org/10.11622/smedj.2022029

Ejemplares similares